Stryker Corp. 10-Q Summary: Q3 2025
Business Context and Reporting Period
This report covers Stryker Corporation's operations for the quarter ended September 30, 2025. Stryker is a global leader in medical technologies, operating through two primary segments: MedSurg and Neurotechnology and Orthopaedics. The period includes the impact of the Q1 2025 acquisition of Inari Medical, Inc. and the Q2 2025 divestiture of the Spinal Implants business.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales ($ millions) | $6,057 | $5,494 | $17,945 | $16,159 |
| Gross Profit ($ millions) | $3,852 | $3,517 | $11,437 | $10,266 |
| Operating Income ($ millions) | $1,135 | $1,085 | $3,085 | $3,108 |
| Net Earnings ($ millions) | $859 | $834 | $2,397 | $2,447 |
| Diluted EPS ($) | $2.22 | $2.16 | $6.20 | $6.35 |
| Operating Margin (%) | 18.7% | 19.7% | 17.2% | 19.2% |
| Cash from Operations (YTD, $ millions) | $2,901 | |||
| Total Debt ($ millions) | $16,595 | |||
| Cash & Equivalents ($ millions) | $3,256 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10.3% in Q3 2025 and 11.1% YTD compared to 2024. Organic growth (excluding acquisitions/divestitures) was 9.5% in Q3 and 10.0% YTD in constant currency.
- Segment Performance: MedSurg and Neurotechnology sales grew 14.4% in Q3, driven by the Inari acquisition and volume increases. Orthopaedics sales grew 3.9% in Q3, impacted by the divestiture of the Spinal Implants business.
- Impairments: Goodwill and other impairments rose significantly to $73 million in Q3 2025 (vs. $2 million in Q3 2024) and $163 million YTD (vs. $21 million in 2024), largely due to the Spinal Implants divestiture and product line exits.
- Acquisition Costs: Selling, general, and administrative (SG&A) expenses increased 15.5% YTD, partially due to a $139 million charge for share-based awards vesting upon the Inari acquisition.
- Debt Structure: Total debt increased to $16.595 billion as the company issued $3 billion in new senior unsecured notes in February 2025 to fund acquisitions and refinance maturing debt.
Outlook, Risks, and Management Commentary
- Adjusted Performance: Management highlights adjusted operating income margins of 25.6% in Q3 and 24.7% YTD, excluding one-time items like impairments and acquisition costs. Adjusted diluted EPS was $3.19 in Q3 and $9.16 YTD.
- Macroeconomic Risks: The company notes risks from new U.S. tariffs on goods from China and the EU, which may increase product costs or impact demand. Geopolitical instability and inflation remain concerns.
- Legal and Regulatory: Stryker is investigating potential Foreign Corrupt Practices Act (FCPA) violations in certain foreign countries; the DOJ inquiry was closed in April 2025 without action, but other investigations continue. The company maintains a $147 million accrual for product liability claims and recalls (e.g., Rejuvenate, ABG II hip stems).
- Divestiture: The sale of the Spinal Implants business was completed in April 2025 for $165 million in proceeds, resulting in significant impairment charges to write down assets to fair value less cost to sell.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and cost synergies associated with the Inari Medical integration, specifically the $139 million stock compensation charge.
- Impairment Details: Review the specific breakdown of the $163 million YTD goodwill and impairment charges to assess if they are recurring or one-time divestiture-related.
- Tariff Exposure: Assess the potential impact of new U.S. tariffs on the cost of goods sold and pricing power in the MedSurg and Orthopaedics segments.
- Legal Accruals: Monitor the $147 million accrual for product liability and recall matters for any material changes in future quarters.
- Debt Servicing: Confirm the impact of the new debt issuances on interest expense, which increased to $453 million YTD from $292 million in the prior year.